Disentangling ERBB Signaling in Breast Cancer Subtypes-A Model-Based Analysis.

ABSTRACT: Targeted therapies have shown striking success in the treatment of cancer over the last years. However, their specific effects on an individual tumor appear to be varying and difficult to predict. Using an integrative modeling approach that combines mechanistic and regression modeling, we gained insights into the response mechanisms of breast cancer cells due to different ligand-drug combinations. The multi-pathway model, capturing ERBB receptor signaling as well as downstream MAPK and PI3K pathways was calibrated on time-resolved data of the luminal breast cancer cell lines MCF7 and T47D across an array of four ligands and five drugs. The same model was then successfully applied to triple negative and HER2-positive breast cancer cell lines, requiring adjustments mostly for the respective

SUBMITTER: Kemmer S 

PROVIDER: S-EPMC9139462 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature